Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. - Wikidata - wikimedia - TriplyDB

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.

http://www.wikidata.org/entity/Q39284803

about

Interleukin-1 inhibitors for acute gout Interleukin-1 in the pathogenesis and treatment of inflammatory diseases Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies The emerging role of biotechnological drugs in the treatment of gout Lighting the fires within: the cell biology of autoinflammatory diseases Targeting interleukin-1 in heart disease Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies Colchicine for the treatment of gout.Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.IL-1 blockade in autoinflammatory syndromes.Relation of temperature and humidity to the risk of recurrent gout attacks.Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis.Cherry consumption and decreased risk of recurrent gout attacks Biologic therapy for autoimmune diseases: an update.Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer New and improved strategies for the treatment of gout Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses.Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study.Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives Nocturnal risk of gout attacks.An expanding role for interleukin-1 blockade from gout to cancer.Autoinflammation: translating mechanism to therapy.An update on the pathology and clinical management of gouty arthritis.Targeting the inflammasome in rheumatic diseases.The Role of NLR-related Protein 3 Inflammasome in Host Defense and Inflammatory Diseases.Treatment and management of pseudogout: insights for the clinician.β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares.Refractory gout attack.Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion Latest evidence on gout management: what the clinician needs to know Enhanced interleukin-1β production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.Uric acid as a danger signal in gout and its comorbidities 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.Purine-rich foods intake and recurrent gout attacks.Low-dose aspirin use and recurrent gout attacks.Treating inflammation by blocking interleukin-1 in humans.Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases

P2860

Q24193902-F9B49DB6-739C-4E75-80AD-9398898971B6 Q24606766-E6C8DCE1-F792-4000-83C8-957B9566FC13 Q26799747-02981D98-2D8B-43A2-AE0C-2E2B261A10DF Q26825459-DB281AC1-730B-44CB-96CC-62C7AEBD887B Q26827163-850638CF-2011-4AA6-951D-6E6FC4DF121E Q27009347-7EB22F0D-C66D-469A-BF7F-78E63F9C10C7 Q33661359-D276BD61-ACFD-4E57-811C-75EA4A14AC02 Q33738046-F2C21F91-6D0D-41F3-B826-C38AE280F918 Q33953931-C41C620D-D4E3-47B7-9CB8-E235B32E5B3B Q34262561-AB131C8C-C52F-4369-BB33-538641ECBE3E Q34285744-A412741E-574E-4914-8125-E47EFA00DCC8 Q34322559-857D58EF-C565-44C0-BF16-B625442592B6 Q34643290-7939D339-EC53-40D9-9803-807A7C193767 Q34655597-A3F7FF2C-44B6-4990-9ECD-B5A91BA40502 Q35012174-9549214D-8206-4B44-BF89-69CD92CF9B54 Q35016934-21CA255D-0785-4F51-87F3-3665D7B922C8 Q35026692-9FB81642-B1BA-4DC7-91D2-617685B15BB9 Q35028032-6B067CF4-12F0-415F-AEB3-523EEC0BC45D Q35092969-D29DD4D9-BFE7-40EA-8C5D-7CCB191674A4 Q35133812-24109F97-AC7E-4CFB-8C79-9215995C6890 Q35180358-5DE032F1-5D4D-4E9C-A8B9-B3F7C3F39CAF Q35219001-9FD96972-FA0B-4084-A84A-3D4E5FE410AD Q35558406-C324C874-EB89-4237-BFFA-12291AD1D68E Q35643985-3E3DF7FA-29F1-42E8-A608-EFA3317A4048 Q35804717-8F999177-58EC-4AAD-80D5-D37FD3B8F47C Q35875538-C0734029-0261-4846-83AD-1A184A3F9654 Q36059527-9673DBB7-923E-4BFC-9021-B3FB8D6A05C6 Q36294205-E712FBFF-2CE0-47D9-B398-93FF8CA45FF3 Q36469680-17F48D3F-B6CA-4520-A3CD-D82298E84337 Q36497205-4BE93383-7049-45FC-88B4-D17DCD6D9D3B Q36515484-0AC7E2E9-1145-40F7-BC42-2AF730423118 Q36633278-A43CBC38-2F46-4C88-BE70-738AA54E3D69 Q36816872-49F9C77F-E6D7-43C2-8E5D-309E62CCBCF2 Q36829387-22889234-FAB8-4311-9194-3282ECB3CC9F Q36870924-387B1719-B2C0-4945-9306-CC132FEBB2F7 Q36903272-589B9FE2-3B40-4D22-A90B-714BA75803C9 Q37469174-34A91D5C-AE19-484A-96C2-582AECBEBC4C Q37517681-D65E3E3D-7521-4E86-BCAE-A323B0CC32C0 Q37636664-5FE4CA8D-252C-4519-B152-CD284BF44AC3 Q37690784-637B54B2-E022-46AF-9BF6-558EF47C9B8D

P2860

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.

http://www.wikidata.org/entity/Q39284803

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Canakinumab for the treatment ...... phase II, dose-ranging study.

@en

Canakinumab for the treatment ...... phase II, dose-ranging study.

@nl

type

label

Canakinumab for the treatment ...... phase II, dose-ranging study.

@en

Canakinumab for the treatment ...... phase II, dose-ranging study.

@nl

prefLabel

Canakinumab for the treatment ...... phase II, dose-ranging study.

@en

Canakinumab for the treatment ...... phase II, dose-ranging study.

@nl

P1433

Q39284803-87415FAF-ED9B-408C-B040-F91FC1F1ADA7

P1476

Q39284803-71367618-6859-4F2F-BCE9-BE917E05AEAB

P2093

Q39284803-0818405D-C382-43A3-9EED-B90E11608DB0

Q39284803-296DF3AA-41FB-4DF3-BB13-108F4FC19EBD

Q39284803-2D5A9797-BF79-49B5-963D-6A273106AAC7

Q39284803-51D169DF-2FD0-4976-9127-A34EE025CE67

Q39284803-7EF71F14-E8D2-422D-9E76-8F1DC7C3F954

Q39284803-9B092A02-4B08-4B51-A4E9-7D5BAE5B00D2

Q39284803-A54F7B05-BB47-4553-8B9C-9FC87096CC8E

Q39284803-DF895854-8099-45C1-BDBB-CFACEC5DD58F

Q39284803-E07DE3B6-6AB2-4373-B654-0CBC6D4AAE9D

P304

Q39284803-49D31170-7968-4A48-98E9-6A7460AAF2B9

P31

Q39284803-3F03A0DC-8884-49D2-AD59-01602C579809

P356

Q39284803-39EAC93D-8932-4D5F-A314-0F49DD5B3DAC

P433

Q39284803-CCEF791B-63EC-46CC-960F-DCA7863BC89B

P478

Q39284803-8CDEA210-5751-4A01-9BC1-DFC4EC9902E2

P577

Q39284803-E5806570-137B-4164-A25E-E3AB767CADD8

P5875

Q39284803-2CA92B4A-4460-4FB9-B763-184A3214540B

P698

Q39284803-4493B44A-FE71-432D-AE00-F6A78DF21F04

P921

Q39284803-0BA7AC51-E2EC-42EF-B9B9-295709D0C539

P356

P1433

Arthritis & Rheumatology

P1476

Canakinumab for the treatment ...... phase II, dose-ranging study.

@en

P2093

A Eftal Yücel

http://www.w3.org/2001/XMLSchema#string

Alexander So

http://www.w3.org/2001/XMLSchema#string

Andrey Pikhlak

http://www.w3.org/2001/XMLSchema#string

Dominik Richard

http://www.w3.org/2001/XMLSchema#string

Marc De Meulemeester

http://www.w3.org/2001/XMLSchema#string

Naomi Schlesinger

http://www.w3.org/2001/XMLSchema#string

Peter Sallstig

http://www.w3.org/2001/XMLSchema#string

Udayasankar Arulmani

http://www.w3.org/2001/XMLSchema#string

Valda Murphy

http://www.w3.org/2001/XMLSchema#string

P304

3064-3076

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.27600

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44659182

http://www.w3.org/2001/XMLSchema#string

P698

20533546

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial